252,000 Shares in MiMedx Group, Inc $MDXG Purchased by Hussman Strategic Advisors Inc.

Hussman Strategic Advisors Inc. bought a new position in shares of MiMedx Group, Inc (NASDAQ:MDXG) during the third quarter, Holdings Channel.com reports. The firm bought 252,000 shares of the company’s stock, valued at approximately $1,759,000.

Several other institutional investors have also recently bought and sold shares of MDXG. Royal Bank of Canada lifted its stake in shares of MiMedx Group by 1.4% during the first quarter. Royal Bank of Canada now owns 982,532 shares of the company’s stock valued at $7,466,000 after acquiring an additional 13,629 shares during the period. AQR Capital Management LLC raised its holdings in MiMedx Group by 42.6% during the 1st quarter. AQR Capital Management LLC now owns 14,374 shares of the company’s stock worth $109,000 after purchasing an additional 4,296 shares during the last quarter. Jacobs Levy Equity Management Inc. bought a new position in shares of MiMedx Group in the 1st quarter valued at about $232,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in shares of MiMedx Group by 5.8% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 73,518 shares of the company’s stock worth $559,000 after buying an additional 4,049 shares during the period. Finally, Millennium Management LLC raised its stake in shares of MiMedx Group by 93.9% during the first quarter. Millennium Management LLC now owns 1,230,984 shares of the company’s stock worth $9,355,000 after buying an additional 596,016 shares during the last quarter. Institutional investors own 79.15% of the company’s stock.

Wall Street Analysts Forecast Growth

MDXG has been the subject of a number of recent analyst reports. Wall Street Zen raised MiMedx Group from a “buy” rating to a “strong-buy” rating in a research note on Sunday, November 2nd. Mizuho cut their price target on shares of MiMedx Group from $12.00 to $10.00 and set an “outperform” rating on the stock in a research report on Wednesday, December 17th. Weiss Ratings restated a “hold (c)” rating on shares of MiMedx Group in a report on Monday, December 29th. Finally, Lake Street Capital lowered their target price on shares of MiMedx Group from $12.00 to $10.00 and set a “buy” rating for the company in a research note on Tuesday, January 20th. Three analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $10.67.

MiMedx Group Price Performance

NASDAQ MDXG opened at $5.30 on Wednesday. The company has a debt-to-equity ratio of 0.07, a quick ratio of 3.95 and a current ratio of 4.41. The stock has a market cap of $784.94 million, a price-to-earnings ratio of 19.63 and a beta of 1.57. The business has a 50 day simple moving average of $6.51 and a 200 day simple moving average of $6.85. MiMedx Group, Inc has a 52-week low of $5.13 and a 52-week high of $9.30.

MiMedx Group (NASDAQ:MDXG) last announced its earnings results on Wednesday, October 29th. The company reported $0.15 earnings per share for the quarter, topping analysts’ consensus estimates of $0.07 by $0.08. The firm had revenue of $113.73 million during the quarter, compared to analyst estimates of $94.74 million. MiMedx Group had a net margin of 10.38% and a return on equity of 27.19%. Analysts anticipate that MiMedx Group, Inc will post 0.3 earnings per share for the current fiscal year.

Insider Buying and Selling at MiMedx Group

In related news, insider Kimberly Maersk-Moller sold 58,300 shares of the stock in a transaction on Thursday, November 6th. The shares were sold at an average price of $7.42, for a total transaction of $432,586.00. Following the completion of the transaction, the insider owned 236,982 shares in the company, valued at approximately $1,758,406.44. This represents a 19.74% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 1.70% of the stock is owned by corporate insiders.

About MiMedx Group

MiMedx Group, Inc is a biopharmaceutical company focused on the development, manufacture and marketing of regenerative biomaterial products derived from human placental tissues. The company’s core mission centers on harnessing the extracellular matrix and growth factors within amniotic and chorionic membranes to support wound healing and surgical applications. MiMedx’s product line leverages proprietary purification processes designed to retain native tissue properties while ensuring sterility and safety.

MiMedx’s principal offerings include amnion/chorion allografts branded under names such as EpiFix® and AmnioFix®, which are indicated for the treatment of acute and chronic wounds—including diabetic foot ulcers, venous leg ulcers and surgical site repair.